Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pliant Therapeutics (PLRX) Change in Account Payables (2019 - 2025)

Pliant Therapeutics (PLRX) has disclosed Change in Account Payables for 7 consecutive years, with -$3000.0 as the latest value for Q4 2025.

  • Quarterly Change in Account Payables rose 99.68% to -$3000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$5.5 million through Dec 2025, down 483.75% year-over-year, with the annual reading at -$5.5 million for FY2025, 483.75% down from the prior year.
  • Change in Account Payables for Q4 2025 was -$3000.0 at Pliant Therapeutics, up from -$897000.0 in the prior quarter.
  • The five-year high for Change in Account Payables was $3.7 million in Q3 2024, with the low at -$4.2 million in Q2 2025.
  • Average Change in Account Payables over 5 years is -$77150.0, with a median of $24500.0 recorded in 2022.
  • The sharpest move saw Change in Account Payables plummeted 2163.16% in 2022, then surged 1936.54% in 2023.
  • Over 5 years, Change in Account Payables stood at $490000.0 in 2021, then tumbled by 427.55% to -$1.6 million in 2022, then surged by 173.02% to $1.2 million in 2023, then tumbled by 179.35% to -$930000.0 in 2024, then skyrocketed by 99.68% to -$3000.0 in 2025.
  • According to Business Quant data, Change in Account Payables over the past three periods came in at -$3000.0, -$897000.0, and -$4.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.